down arrow

Rocket Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US77313F1066
USD
3.42
0.33 (10.68%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.323.46

52 Week

2.1915.00
Valuation
Technical
Day's Volume

CASH

1.06 M

Shareholding (Mar 2025)

FII

11.17%

Held by 121 FIIs

DII

50.8%

Held by 47 DIIs

Promoter

4.27%

How big is Rocket Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Rocket Pharmaceuticals, Inc. has a market capitalization of 293.05 million and reported net sales of 0.00 million with a net profit of -258.03 million over the latest four quarters. Shareholder's funds are 463.23 million, and total assets amount to 527.70 million.

As of Jun 18, Rocket Pharmaceuticals, Inc. has a market capitalization of 293.05 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -258.03 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 463.23 million and total assets of 527.70 million.

Read More

What does Rocket Pharmaceuticals, Inc. do?

22-Jun-2025

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases, with a market cap of approximately $293 million and a net profit of -$61 million as of March 2025. The company has no dividend yield and negative financial metrics, indicating it is currently loss-making.

Overview: <BR>Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapy treatment options for rare, devastating diseases within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -61 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 293.05 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: -62.77% <BR>Price to Book: 0.71<BR><BR>Contact Details: <BR>Address: 350 5th Ave Ste 7530, NEW YORK NY: 10118-7501 <BR>Tel: 1 646 4409100 <BR>Fax: 1 781 6762155 <BR>Website: https://www.rocketpharma.com/

Read More

Who are in the management team of Rocket Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Rocket Pharmaceuticals, Inc. includes Dr. Roderick Wong (Chairman), Dr. Gaurav Shah (CEO), and several independent directors: Mr. David Southwell, Dr. Elisabeth Bjork, Mr. Carsten Boess, Mr. Pedro Granadillo, and Dr. Gotham Makker. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Rocket Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Roderick Wong, Chairman of the Board<BR>- Dr. Gaurav Shah, President, Chief Executive Officer, and Director<BR>- Mr. David Southwell, Director<BR>- Dr. Elisabeth Bjork, Independent Director<BR>- Mr. Carsten Boess, Independent Director<BR>- Mr. Pedro Granadillo, Independent Director<BR>- Dr. Gotham Makker, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Rocket Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 11, 2025, Rocket Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

As of 11 August 2025, the technical trend for Rocket Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bearish stance weekly and bearish monthly. Daily moving averages are mildly bearish, and the KST reflects a mildly bullish trend weekly but bearish monthly. According to Dow Theory, there is a mildly bearish trend on the weekly chart with no trend on the monthly.<BR><BR>In terms of performance, Rocket Pharmaceuticals has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -74.78% compared to the S&P 500's 12.22%, and a one-year return of -84.79% versus 17.14% for the index. Overall, the current technical stance is mildly bearish.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 352 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.76

stock-summary
Return on Equity

-71.63%

stock-summary
Price to Book

0.99

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-69 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.01%
0%
3.01%
6 Months
15.54%
0%
15.54%
1 Year
-74.67%
0%
-74.67%
2 Years
-85.4%
0%
-85.4%
3 Years
-82.8%
0%
-82.8%
4 Years
-84.99%
0%
-84.99%
5 Years
-89.87%
0%
-89.87%

Rocket Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Rocket Pharmaceuticals, Inc. technically bullish or bearish?

As of 11 August 2025, the technical trend for Rocket Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bearish stance weekly and bearish monthly. Daily moving averages are mildly bearish, and the KST reflects a mildly bullish trend weekly but bearish monthly. According to Dow Theory, there is a mildly bearish trend on the weekly chart with no trend on the monthly. In terms of performance, Rocket Pharmaceuticals has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -74.78% compared to the S&P 500's 12.22%, and a one-year return of -84.79% versus 17.14% for the index. Overall, the current technical stance is mildly bearish....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-201.00%
EBIT to Interest (avg)
-96.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.80
EV to EBIT
-0.06
EV to EBITDA
-0.06
EV to Capital Employed
0.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-279.01%
ROE (Latest)
-62.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 59 Schemes (33.74%)

Foreign Institutions

Held by 121 Foreign Institutions (11.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 1.01% vs -5.94% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.10",
          "val2": "-71.40",
          "chgp": "8.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.60",
          "val2": "0.70",
          "chgp": "-614.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-68.90",
          "val2": "-69.60",
          "chgp": "1.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.33% vs -10.68% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-263.80",
          "val2": "-252.60",
          "chgp": "-4.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-258.70",
          "val2": "-245.60",
          "chgp": "-5.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-65.10
-71.40
8.82%
Interest
0.50
0.50
Exceptional Items
-3.60
0.70
-614.29%
Consolidate Net Profit
-68.90
-69.60
1.01%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 1.01% vs -5.94% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-263.80
-252.60
-4.43%
Interest
1.90
1.90
Exceptional Items
-1.90
0.00
Consolidate Net Profit
-258.70
-245.60
-5.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.33% vs -10.68% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Rocket Pharmaceuticals, Inc. stock-summary
stock-summary
Rocket Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.
Company Coordinates stock-summary
Company Details
350 5th Ave Ste 7530 , NEW YORK NY : 10118-7501
stock-summary
Tel: 1 646 4409100
stock-summary
https://www.rocketpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."